Enterovirus A71 Vaccines

Mei-Ling Li; Shin-Ru Shih; Blanton S Tolbert; Gary Brewer

doi:10.3390/vaccines9030199

Enterovirus A71 Vaccines

Vaccines (Basel). 2021 Feb 27;9(3):199. doi: 10.3390/vaccines9030199.

Authors

Mei-Ling Li¹, Shin-Ru Shih^{2

3

4

5}, Blanton S Tolbert⁶, Gary Brewer¹

Affiliations

¹ Department of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
² Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
³ Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
⁴ Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
⁵ Research Center for Chinese Herbal Medicine, Research Center for Food and Cosmetic Safety, and Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan.
⁶ Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA.

Abstract

Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.

Keywords: Enterovirus A71; Sinovac; foot and mouth disease (HFMD); hand; vaccine.

Publication types

Review

Abstract

Publication types

Grants and funding